| Literature DB >> 26889385 |
Batoul Khoundabi1, Anoshirvan Kazemnejad1, Marjan Mansourian2, Elham Faghihimani3.
Abstract
BACKGROUND: The globally increasing epidemic of diabetes will lead to serious problems including diabetic nephropathy and kidney diseases in near future. The first clinical diagnosable stage in a diabetic kidney disease is microalbuminuria (urinary albumin excretion of 30 - 300 g/24 hours).Entities:
Keywords: Diabetes Mellitus Type 2; Risk Factors; Serum Albumin
Year: 2016 PMID: 26889385 PMCID: PMC4752729 DOI: 10.5812/ircmj.20671
Source DB: PubMed Journal: Iran Red Crescent Med J ISSN: 2074-1804 Impact factor: 0.611
Clinical Characteristics of All Patients in the Outset of the Study and the Follow-up Years
| Variable | Outset | 1st Year | 2nd Year | 3rd Year | 4th Year | 5th Year | 6th Year |
|---|---|---|---|---|---|---|---|
|
| 192.6 ± 53.2 | 169.5 ± 56.9 | 146.5 ± 53.7 | 148.5 ± 57.7 | 147.7 ± 57.2 | 131.9 ± 59.7 | 108.5 ± 66.6 |
|
| 227.9 ± 50.7 | 233.1 ± 43.7 | 222.1 ± 51.6 | 236.9 ± 55.8 | 231.3 ± 52.1 | 217.6 ± 42.9 | 220.1 ± 45.1 |
|
| 82.2 ± 10.4 | 82.8 ± 11.8 | 81.5 ± 9.2 | 82.6 ± 9.4 | 83.5 ± 9.8 | 84.2 ± 8.9 | 83.5 ± 9.5 |
|
| 10.9 ± 2.2 | 10.8 ± 2.1 | 10.4 ± 2.2 | 9.6 ± 1.7 | 8.5 ± 2.2 | 7.9 ± 1.6 | 8.0 ± 1.3 |
|
| 44.1 ± 12.4 | 43.9 ± 15.4 | 44.9 ± 13.1 | 46.9 ± 11.9 | 46.5 ± 10.7 | 47.1 ± 12.2 | 49.5 ± 10.7 |
|
| 135.6 ± 20.6 | 137.7 ± 24.4 | 129.8 ± 18.9 | 134.1 ± 21.3 | 133.5 ± 17.7 | 138.0 ± 18.5 | 139.2 ± 20.9 |
|
| 25.9 ± 4.5 | 25.9 ± 4.2 | 26.2 ± 4.1 | 26.4 ± 4.2 | 26.9 ± 4.6 | 27.4 ± 4.5 | 27.6 ± 4.2 |
|
| 114.5 ± 151.8 | 121.2 ± 116.6 | 123.3 ± 120.1 | 128.6 ± 136.8 | 146.1 ± 130.6 | 150.1 ± 140.2 | 160.8 ± 150.6 |
|
| 191.9 ± 86.5 | 190.9 ± 64.9 | 186.3 ± 83.9 | 191.0 ± 73.7 | 192.6 ± 76.6 | 192.6 ± 62.9 | 162.1 ± 85.7 |
Abbreviations: BMI, body mass index; DBP, diastolic blood pressure; FBS, fast blood sugar; HBA1c, hemoglobin A1c; HDL, high-density lipoprotein; TCL, total cholesterol; SA, serum albumin; SBP, systolic blood pressure; TG, triglyceride.
Figure 1.Serum Albumin Measurements Over Time for Five Randomly Selected Patients
Bayes Estimates and 95% Highest Posterior Density HPD Intervals of Model Parameters Under the Symmetric and Skew-Symmetric Distributions[a]
| Variables | Model (a) | Model (b) | Model (c) | Model (d) |
|---|---|---|---|---|
|
| ||||
| Bayes estimates | 3.49[ | 2.56[ | 2.94[ | 2.96[ |
| 95% HPD intervals | (0.61, 6.37) | (0.20, 4.92) | (0.38, 5.50) | (0.38, 5.54) |
|
| ||||
| Bayes estimates | 2.59 | 2.34 | 2.87 | 2.87 |
| 95% HPD intervals | (-0.26, 5.44) | (-0.22, 4.90) | (-0.12, 5.86) | (-0.03, 5.77) |
|
| ||||
| Bayes estimates | -0.85[ | -0.73[ | -0.77[ | 0.76[ |
| 95% HPD intervals | (-1.50, -0.20) | (-1.40, -0.06) | (-1.33, -0.21) | (-1.34, -0.18) |
|
| ||||
| Bayes estimates | -0.44 | -0.40 | -0.43 | - 0.42 |
| 95% HPD intervals | (-1.94, 1.06) | (-1.50, 0.70) | (-1.63, 0.77) | (1.63, 0.79) |
|
| ||||
| Bayes estimates | -0.01 | -0.01 | -0.01 | -0.01 |
| 95% HPD intervals | (-0.26, 0.24) | (-0.24, 0.22) | (-0.25, 0.23) | (-0.24, 0.24) |
|
| ||||
| Bayes estimates | -0.09 | -0.08 | -0.09 | -0.08 |
| 95% HPD intervals | (-0.23, 0.05) | (-0.22, 0.06) | (-0.24, 0.06) | (-0.23, 0.07) |
|
| ||||
| Bayes estimates | 0.10 | 0.09 | 0.09 | 0.09 |
| 95% HPD intervals | (-0.01, 0.21) | (-0.01, 0.19) | (-0.01, 0.19) | (-0.01, 0.21) |
|
| ||||
| Bayes estimates | 0.18[ | 0.19[ | 0.20[ | 0.20[ |
| 95% HPD intervals | (0.01, 0.35) | (0.03, 0.35) | (0.04, 0.36) | (0.04, 0.36) |
|
| 99.7 | 56.2 | 60.6 | 59.0 |
Abbreviations: BMI, body mass index; DBP, diastolic blood pressure; DD, duration of diabetes; DIC, deviance information criterion; FBS, fast blood sugar; HBA1c, hemoglobin A1c; HDL, high-density lipoprotein; HPD, highest posterior density; TCL, total cholesterol; SA, serum albumin; SBP, systolic blood pressure; TG, triglyceride.
aDistribution of residuals and random intercepts in: model (a) normal and normal, model (b) skew-t and skew-t, model (c) normal and skew-slash, model (d) Laplace and skew-t.
bSignificance of the effect at the significance level of 5%.